サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：分娩後出血治療の世界市場-2023-2030年
市場調査レポート
商品コード
1352180

分娩後出血治療の世界市場-2023-2030年

Global Postpartum Hemorrhage Treatment Market - 2023-2030

出版日
ページ情報
英文 195 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
分娩後出血治療の世界市場-2023-2030年
出版日: 2023年09月27日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

分娩後出血治療の市場動向は、技術進歩や研究者間の協力関係の高まりにより、調査研究が活発化していることを示しています。世界の妊産婦死亡の最大の原因は分娩後出血（PPH）であり、分娩後24時間以内に500ミリリットルを超える出血が起こることと定義されています。

世界保健機関（WHO）によれば、年間約1,400万人の女性が罹患し、7万人以上の死亡の原因となっています。さらに、承認された技術の利用可能性の高まりと市場における分娩後出血に関連する死亡者数の増加により、分娩後出血の治療が増加し、分娩後出血治療の市場規模を押し上げています。

この分野での進歩の高まりにより、北米の治療需要が伸びています。テレフレックス・インコーポレイテッド、クック、ユタ・メディカル・プロダクツ、オルガノン・グループなどの競合企業が積極的に市場に参入しているため、市場は今後成長すると思われます。

ダイナミクス

研究機関による研究開発の拡大が分娩後出血治療市場の成長を牽引

分娩後出血治療技術は現在、分子医学、特にバイオマーカーの同定に広く応用されています。バーミンガム大学と世界保健機関（WHO）の研究者が発表した画期的な調査によると、E-MOTIVEとして知られる新しいアプローチは、出産関連の出血による死亡率を大幅に減少させる可能性があります。

提案されたE-MOTIVEキットは、PPHを早期かつ正確に検出するための採血用ドレープで構成されています。子宮マッサージ、子宮を圧迫して出血を止めるための薬剤、点滴の投与、評価、そして必要であれば先進医療へのエスカレーションを含む緊急治療パッケージが、適応があればこれに加えられます。

実験中のE-MOTIVE介入を支援するために、専門的なトレーニング、分娩後出血用トロリーまたはキャリーケース、地域のチャンピオンの協力、監査、フィードバックを含む実施計画が用いられました。助産師はE-MOTIVEの介入のすべてのステップを完了することができます。この市場は、高い調査研究により予測期間を通じて主導権を握ると予測されています。

政府や非政府組織による戦略的イニシアチブの拡大が市場成長の機会を生み出す

国際産科婦人科連合（FIGO）は、世界の妊産婦死亡率および妊産婦障害の低減に向けた取り組みを積極的に支援しています。FIGOの目標声明は、すべての女性の健康、人権、ウェルネス、特に出産の結果として死亡したり障害者になったりする最大のリスクに直面する女性の健康、人権、ウェルネスを推進することへの献身を反映しています。FIGOのエビデンスに基づく介入は、十分な説明を受けた上で使用されれば、妊産婦の病気や死亡の頻度を下げることができます。

高所得国では、死亡率の高いPPHのような疾患を管理するために、複数の方法が用いられてきました。様々な病態の管理を確立し、徹底的に対処する学際的プログラムだけでなく、多くの介入の実施により、これらのイニシアチブは構成され、「バンドル」または介入パッケージとして知られる多数の介入ポイントやアクターが関与しています。バンドルは、体系化された実施と診療の均一化を促進する方法で、すでに存在する推奨事項やガイドラインの選択を提供するものです。

各構成要素に高いアドヒアランスがあれば、バンドルケア戦略は患者の転帰を高めることができるとFIGOは考えています。使用可能なバンドルは数多くあり、すべての医療システムが1つを採用する必要があります。すべての産科病院にバンドルを配置し、患者が産科に到着してから、より高次のケアに移行するまで、そのすべての構成要素に対するトレーニングを提供します。

治療に伴う副作用が市場の成長を阻害する

痙攣（発作）、錯乱、呼吸の問題、速いまたは不規則な心拍、めまい、激しいまたは持続的な頭痛、じんましん、皮膚の発疹またはかゆみ、激しい骨盤または腹部の痛み、膣出血の増加または持続的な出血、急激な体重増加、衰弱は、現れる場合と現れない場合があるいくつかの副作用です。

過剰摂取の症状には、震え、落ち着きのなさ、疲労感、不明瞭な言葉、反応の鈍さ、意識障害などがあります。多くの場合、医学的治療を必要としない潜在的な副作用もあります。体が薬に慣れてくると、治療中にこれらの副作用がなくなる可能性もあります。これらの要素は市場の拡大を制限する可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 研究機関による研究開発の拡大
      • 技術革新の高まり
    • 抑制要因
      • 治療に伴う副作用
    • 機会
      • 政府や非政府組織による戦略的イニシアチブの拡大
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 タイプ別

  • 原発性分娩後出血
  • 二次性分娩後出血

第8章 治療法別

  • 薬物療法
    • オキシトシン（ピトシン）
    • カルボプロストトロメタミン（ヘマベート）
    • マレイン酸メチルエルゴノビン（メテルギン）
    • ミソプロストール（サイトテック）
    • ジノプロストン（プロスティンE2）
    • トラネキサム酸（サイクロカプロン）
  • デバイス
    • 子宮タンポナーデ器具
      • フォーリーカテーテル
      • コンドームカテーテル
      • バクリ・タンポナーデ・バルーン
    • 非空圧式アンチショック・ガーメント
    • プレフィルド注入システム

第9章 販売チャネル別

  • 販売チャネル
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • エンドユーザー
    • 病院
    • 外来手術センター
    • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Teleflex Incorporated
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Cook
  • Utah Medical Products, Inc.
  • OBSTETRX
  • BACTIGUARD AB
  • Organon group of companies
  • 3rd Stone Design
  • Pfizer Inc.
  • American Regent, Inc.
  • Ferring B.V.

第13章 付録

目次
Product Code: PH6948

Overview

The postpartum hemorrhage treatment market trends show rising research owing to the rising technological advancements and collaborations among researchers. The biggest cause of maternal death globally is postpartum hemorrhage (PPH), which is defined as the bleeding of over 500 milliliters within 24 hours of giving delivery.

It affects approximately 14 million women annually and contributes to over 70 000 deaths, the most of which occur in low- and middle-income countries, or one every six minutes according to World Health Organization. Furthermore, rising treatments for postpartum hemorrhage due to the rising availability of approved technologies and increase in the number of deaths associated with post partum hemorrhage in the market is driving up the postpartum hemorrhage treatment market size.

The market is experiencing a growth in demand for treatment from North America as a result of the rising advancements in this field. With significant competitors like Teleflex Incorporated, Cook, Utah Medical Products, Inc., and Organon group of companies actively operating in the market, the market will grow in upcoming time.

Dynamics

Growing Research and Development by Research Organizations Drive the Growth of the Postpartum Hemorrhage Treatment Market

Postpartum hemorrhage treatment technology is currently widely applied in molecular medicine, particularly for the identification of biomarkers. According to a landmark study released by researchers from the University of Birmingham and the World Health Organization (WHO), a novel approach known as E-MOTIVE may significantly reduce mortality caused by childbirth-related bleeding.

The suggested E-MOTIVE kit comprises a blood-collection drape for the early and precise detection of PPH. An emergency treatment package that includes uterine massage, drugs to compress the womb and cease the bleeding, administering intravenous fluids, an assessment, and, if necessary, escalation to advanced care, is added to this when it is indicated.

An implementation plan that included specialized training, postpartum hemorrhage trolleys or carry cases, enlisting the help of local champions, audits, and feedback was used to support the E-MOTIVE intervention during the experiment. Midwives can complete every step of the E-MOTIVE intervention. The market is predicted to take the lead throughout the forecast period owing to high research studies.

Rising Strategic Initiatives by Government or Non-Government Organizations Creates Opportunities for the Growth of the Market

The International Federation of Gynecology and Obstetrics, or FIGO, is actively supporting efforts to lower maternal mortality and disability worldwide. Its goal statement reflects a dedication to advancing the health, human rights, and wellness of all women, particularly those who face the greatest risk of passing away or becoming disabled as a result of childbearing. When used with informed permission, FIGO's evidence-based interventions can lower the frequency of maternal illness and mortality.

In high-income countries, multimodal techniques have been used to manage diseases like PPH that have high mortality rates. The implementation of a number of interventions as well as multidisciplinary programs that establish and thoroughly address the management of a variety of pathologies make up these initiatives, which involve numerous intervention points and actors, known as "bundles" or intervention packages. Bundles provide a selection of already-existing recommendations and guidelines in a way that promotes systematized implementation and practice uniformity.

When there is high adherence to each component, FIGO believes the bundle care strategy can enhance patient outcomes. There are numerous bundles that can be used, and every health system needs to adopt one. Place the bundle in every maternity hospital and provide training for all of its components, from the time a patient arrives on the obstetrics department until the time they are transferred to higher level care.

The Side Effects Associated with Treatment will hamper the growth of the market

Convulsions (seizures), confusion, breathing issues, a fast or irregular heartbeat, dizziness, severe or persistent headaches, hives, skin rashes or itching, severe pelvic or abdominal pain, increased or persistent vaginal bleeding, rapid weight gain, and weakness are a few side effects that may or may not manifest.

Overdose symptoms include trembling, restlessness, tiredness, slurred speech, sluggish response times, and unconsciousness. There are certain potential side effects that often do not require medical treatment. As the body gets used to the medication, these side effects could go away during treatment. These elements can limit the market's expansion.

Segment Analysis

The global postpartum hemorrhage treatment market is segmented based type, treatment, sales channel and region.

Owing to High Adoption, the Oxytocin (Pitocin) from Treatment Segment Accounted for Approximately 43.2% of the Postpartum Hemorrhage Treatment Market Share

The oxytocin (Pitocin) category from treatment held the largest market share in 2022 and is expected to maintain its dominance over the forecast period due to a high demend and its high efficacy worldwide. By encouraging the generation of prostaglandins and raising the intracellular calcium ion concentrations in myometrial cells, oxytocin, which is produced by the posterior pituitary, causes an increase in uterine contractions. The upper myometrial segment undergoes regular contractions, which restrict spiral arteries and lessen uterine blood flow.

Individual differences in the amount of myometrial oxytocin receptors affect both the sensitivity and reaction of the uterus to the injection of oxytocin. Oxytocin is produced synthetically to lower the possibility of contamination from vasopressin and additional biologically active peptides. Only after the anterior shoulder delivery is oxytocin given. Oxytocin has a plasma half-life of 1 to 6 minutes. Oxytocin IV patients experience an instantaneous uterine response that lasts for about 60 minutes. In 3 to 5 minutes after administering IM oxytocin, patients experience a 2 to 3 hour long uterine response.

There is currently no dose regimen that has been demonstrated to have greater results than another. The highest oxytocin cumulative dose that is advised is 40 units. Single-dose 1-mL vials of oxytocin and multidose 10-mL vials, both containing 10 units/mL, are available. Vials must be kept at room temperature for storage.

Geographical Penetration

North America Accounted for Approximately 39.9% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment

Due to the rising need for postpartum hemorrhage medication in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for treatment for postpartum hemorrhage.

Increasing expenditure on healthcare and rising research studies, advancement of technologies for treatment purpose, and increase in pharmaceutical and women health business establishment across the region are also contributing to the growth of postpartum hemorrhage treatment market share of this region.

It is also anticipated that the main healthcare organizations' and enterprises' collaborative research projects as well as new product development, which constantly seeks to improve available alternatives, will contribute to the expanding demand. Individuals are becoming more aware of various technologies and treatment for postpartum hemorrhage that are being utilized for management purposes, leading to the expansion of the market in this region. The above-mentioned factors further proves the dominance of North America on a global scale.

Competitive Landscape

The major global players in the postpartum hemorrhage treatment market include Teleflex Incorporated, Cook, Utah Medical Products, Inc., OBSTETRX, BACTIGUARD AB, Organon group of companies, 3rd Stone Design, Pfizer Inc., American Regent, Inc. and Ferring B.V. among others.

COVID-19 Impact Analysis

Russia Ukraine Conflict Analysis

Due to the low prevalence as well as absence of major market participants in this region, it is predicted that the Russia-Ukraine conflict will not have a significant effect on the worldwide postpartum hemorrhage treatment market. The growth of the global postpartum hemorrhage treatment market, however, is anticipated to be relatively unaffected by the import and export of raw materials over the forecast period.

By Type

  • Primary Postpartum Hemorrhage
  • Secondary Postpartum Hemorrhage

By Treatment

  • Medications
    • Oxytocin (Pitocin)
    • Carboprost Tromethamine (Hemabate)
    • Methylergonovine Maleate (Methergine)
    • Misoprostol (Cytotec)
    • Dinoprostone (Prostin E2)
    • Tranexamic Acid (Cyklokapron)
  • Devices
    • Uterine Tamponade Devices
      • Foley Catheter
      • Condom Catheter
      • Bakri Temponade Balloon
  • Non-Pneumatic Anti-Shock Garment
  • Prefilled Injection System

By Sales Channel

  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • End User
    • Hospitals
    • Ambulatory Surgical Centers
    • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On January 10, 2023, following a thorough authorization procedure, Bactiguard announces the approval of its first Medical Device Regulations (MDR) product. The latex BIP Foley Catheter, an indwelling urinary catheter featuring Bactiguard's exclusive infection prevention technology, is the subject of the MDR approval.
  • On October 11, 2021, the U.S. Food and Drug Administration (FDA) has approved the Special 510(k) for technical changes to the Jada System, which is designed to control and treat abnormal Postpartum Hemorrhage Treatment or uterine bleeding when conservative management is necessary, according to Organon, a global women's health company.
  • On July 26, 2021, After nearly ten years of public-private cooperation, Ferring Pharmaceuticals announced the first application of heat-stable carbetocin (Carbetocin Ferring) to stop excessive Postpartum Hemorrhage Treatment (PPH). It is now possible to employ heat-stable carbetocin in hospitals all throughout India to stop excessive bleeding after vaginal and cesarean deliveries.

DMI Opinion:

The global postpartum hemorrhage treatment market is going to see decent growth in upcoming years owing to rising usage of postpartum hemorrhage medication and novel technologies or devices that are being developed. Several researches are taking place worldwide to enhance the management of postpartum hemorrhage. Numerous advances are taking place leading to the growth of market such as uterine tempons or drapes. According to DMI the postpartum hemorrhage treatment market will see a decent growth with several novel treatments in the market.

Why Purchase the Report?

  • To visualize the global postpartum hemorrhage treatment market segmentation based on type, treatment, sales channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of postpartum hemorrhage treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global postpartum hemorrhage treatment market report would provide approximately 62 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Treatment
  • 3.3. Snippet by Sales Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Research and Development by Research Organizations
      • 4.1.1.2. Rising Technological Adavancements
    • 4.1.2. Restraints
      • 4.1.2.1. The Side Effects Associated with Treatment
    • 4.1.3. Opportunity
      • 4.1.3.1. Rising Strategic Initiatives by Government or Non-Government Organizations
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Primary Postpartum Hemorrhage *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Secondary Postpartum Hemorrhage

8. By Treatment

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 8.1.2. Market Attractiveness Index, By Treatment
  • 8.2. Medications *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Oxytocin (Pitocin)
    • 8.2.4. Carboprost Tromethamine (Hemabate)
    • 8.2.5. Methylergonovine Maleate (Methergine)
    • 8.2.6. Misoprostol (Cytotec)
    • 8.2.7. Dinoprostone (Prostin E2)
    • 8.2.8. Tranexamic Acid (Cyklokapron)
  • 8.3. Devices
    • 8.3.1. Uterine Tamponade Devices
      • 8.3.1.1. Foley Catheter
      • 8.3.1.2. Condom Catheter
      • 8.3.1.3. Bakri Temponade Balloon
    • 8.3.2. Non-Pneumatic Anti-Shock Garment
    • 8.3.3. Prefilled Injection System

9. By Sales Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 9.1.2. Market Attractiveness Index, By Sales Channel
  • 9.2. Distribution Channel *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 9.2.3. Hospital Pharmacies
    • 9.2.4. Retail Pharmacies
    • 9.2.5. Online Pharmacies
  • 9.3. End User
    • 9.3.1. Hospitals
    • 9.3.2. Ambulatory Surgical Centers
    • 9.3.3. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 12.4.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.4.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.4.1. Brazil
      • 12.4.4.2. Argentina
      • 12.4.4.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Teleflex Incorporated *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Cook
  • 12.3. Utah Medical Products, Inc.
  • 12.4. OBSTETRX
  • 12.5. BACTIGUARD AB
  • 12.6. Organon group of companies
  • 12.7. 3rd Stone Design
  • 12.8. Pfizer Inc.
  • 12.9. American Regent, Inc.
  • 12.10. Ferring B.V.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us